Literature DB >> 9870256

The antiviral prophylaxis of post-transplant lymphoproliferative disorder.

C L Davis1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9870256     DOI： 10.1007/BF00838054

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN： 0344-4325


× No keyword cloud information.
  161 in total

1.  Cloning and expression of a cDNA encoding the Epstein-Barr virus thymidine kinase gene.

Authors:  M Y Liu; C Y Pai; S M Shieh; T Y Hsu; J Y Chen; C S Yang
Journal:  J Virol Methods       Date:  1992-10       Impact factor: 2.014

2.  Lymphoproliferative disease in a cotton-top marmoset after inoculation with infectious mononucleosis-derived Epstein-Barr virus.

Authors:  J Werner; H Wolf; J Apodaca; H zur Hausen
Journal:  Int J Cancer       Date:  1975-06-15       Impact factor: 7.396

3.  Does intravenous immunoglobulin prevent primary cytomegalovirus disease in kidney transplant recipients?

Authors:  N Khawand; J A Light; W Brems; A Aquino; A Ali
Journal:  Transplant Proc       Date:  1989-02       Impact factor: 1.066

Review 4.  The diagnosis and treatment of posttransplant lymphoproliferative disorders.

Authors:  M A Nalesnik; L Makowka; T E Starzl
Journal:  Curr Probl Surg       Date:  1988-06       Impact factor: 1.909

5.  Studies on long-term T-cell-mediated immunity to Epstein-BArr virus in immunosuppressed renal allograft recipients.

Authors:  D H Crawford; J M Edwards; P Sweny; A V Hoffbrand; G Janossy
Journal:  Int J Cancer       Date:  1981-12       Impact factor: 7.396

6.  Epstein-Barr virus LMP1 induction of the epidermal growth factor receptor is mediated through a TRAF signaling pathway distinct from NF-kappaB activation.

Authors:  W E Miller; G Mosialos; E Kieff; N Raab-Traub
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

7.  Switching viral latency to viral lysis: a novel therapeutic approach for Epstein-Barr virus-associated neoplasia.

Authors:  M I Gutiérrez; J G Judde; I T Magrath; K G Bhatia
Journal:  Cancer Res       Date:  1996-03-01       Impact factor: 12.701

8.  Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients.

Authors:  S A Riddler; M C Breinig; J L McKnight
Journal:  Blood       Date:  1994-08-01       Impact factor: 22.113

9.  A recent decrease in the time to development of monomorphous and polymorphous posttransplant lymphoproliferative disorder.

Authors:  E J Alfrey; A L Friedman; R A Grossman; L J Perloff; A Naji; C F Barker; K T Montone; J E Tomaszewski; C Chmielewski; T Holland
Journal:  Transplantation       Date:  1992-08       Impact factor: 4.939

10.  Management of lymphoproliferative disorders after cardiac transplantation.

Authors:  J M Chen; M L Barr; A Chadburn; G Frizzera; F A Schenkel; R R Sciacca; D S Reison; L J Addonizio; E A Rose; D M Knowles
Journal:  Ann Thorac Surg       Date:  1993-09       Impact factor: 4.330
View more
  4 in total

Review 1.  The role of EBV in post-transplant malignancies: a review.

Authors:  P Hopwood; D H Crawford
Journal:  J Clin Pathol       Date:  2000-04       Impact factor: 3.411

Review 2.  Pediatric post-transplant lymphoproliferative disorder after cardiac transplantation.

Authors:  Hideaki Ohta; Norihide Fukushima; Keiichi Ozono
Journal:  Int J Hematol       Date:  2009-08-12       Impact factor: 2.490

Review 3.  Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy.

Authors:  Anat Gafter-Gvili; Abigail Fraser; Mical Paul; Liat Vidal; Theresa A Lawrie; Marianne D van de Wetering; Leontien C M Kremer; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2012-01-18

4.  An MHV-68 Mutator Phenotype Mutant Virus, Confirmed by CRISPR/Cas9-Mediated Gene Editing of the Viral DNA Polymerase Gene, Shows Reduced Viral Fitness.

Authors:  Erika Trompet; Arturo Temblador; Sarah Gillemot; Dimitrios Topalis; Robert Snoeck; Graciela Andrei
Journal:  Viruses       Date:  2021-05-26       Impact factor: 5.048
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.